A PHASE 1B DOSE-RANGING STUDY OF 4 WEEKS OF PEG-INTERFERON (IFN) LAMBDA (PEG-RIL-29) IN COMBINATION WITH RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION

被引：0
|
作者：
Muir, Andrew [1 ]
Shiffman, Mitchell L. [2 ]
Zaman, Atif [3 ]
Yoffe, Boris [4 ]
Lopez-Talavera, Juan Carlos [5 ]
Souza, Sherri [6 ]
Hausman, Diana F. [6 ]
Lawitz, Eric [7 ]
机构：
[1] Duke Univ, Durham, NC USA
[2] VCU Med Ctr, Richmond, VA USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] Baylor Coll Med, Houston, TX 77030 USA
[5] Bristol Myers Squibb Co, New York, NY 10154 USA
[6] ZymoGenetics Inc, Seattle, WA USA
[7] Alamo Med Res, San Antonio, TX USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1591
引用
收藏
页码：1039A / 1040A
页数：2
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN A DOSE-RANGING PHASE 1B STUDY IN HEPATITIS C PATIENTS
    Byrnes-Blake, K. A.
    Freeman, J. A.
    Dodds, M. G.
    Rapalus, L.
    Pederson, S.
    Hunder, N.
    Miller, D. M.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S117 - S117
  • [2] INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN
    Lawitz, Eric J.
    Zaman, Atif
    Muir, Andrew J.
    Shiffman, Mitchell L.
    Yoffe, Boris
    Zhang, Tracy
    Souza, Sherri
    Hausman, Diana F.
    HEPATOLOGY, 2008, 48 (04) : 385A - 385A
  • [3] A PHASE 2, RANDOMIZED STUDY OF HCV-796 IN COMBINATION WITH PEGYLATED-INTERFERON (PEG) PLUS RIBAVIRIN (RBV) VERSUS PEG PLUS RBV IN HEPATITIS C VIRUS GENOTYPE-1 INFECTION
    Pockros, P.
    Rodriguez-Torres, M.
    Villano, S.
    Maller, E.
    Chojkier, M.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S7 - S8
  • [4] Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection
    Muir, Andrew J.
    Shiffinan, Mitchell L.
    Zaman, Atif
    Yoffe, Boris
    de la Torre, Andrew
    Flamm, Steven
    Gordon, Stuart C.
    Marotta, Paul
    Vierling, John M.
    Lopez-Talavera, Juan Carlos
    Byrnes-Blake, Kelly
    Fontana, David
    Freeman, Jeremy
    Gray, Todd
    Hausman, Diana
    Hunder, Naomi N.
    Lawitz, Eric
    HEPATOLOGY, 2010, 52 (03) : 822 - 832
  • [5] Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse
    Lagging, Martin
    Rembeck, Karolina
    Buhl, Mads Rauning
    Christensen, Peer
    Dalgard, Olav
    Farkkila, Martti
    Hellstrand, Kristoffer
    Langeland, Nina
    Lindh, Magnus
    Westin, Johan
    Norkrans, Gunnar
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (07) : 839 - 847
  • [6] THE EFFECT OF TREATMENT GROUP, HCV GENOTYPE, AND IL28B GENOTYPE ON EARLY HCV VIRAL KINETICS IN A PHASE 2A STUDY OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN HEPATITIS C PATIENTS
    Freeman, Jeremy A.
    Gray, Todd E.
    Fontana, David
    Lopez-Talavera, Juan Carlos
    Miller, Dennis M.
    Hillson, Jan L.
    HEPATOLOGY, 2010, 52 (04) : 721A - 721A
  • [7] Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin:: 24 weeks of therapy are sufficient for HCV genotype 2 and 3
    Cornberg, M
    Hüppe, D
    Wiegand, J
    Felten, G
    Wedemeyer, H
    Manns, MP
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2003, 41 (06): : 517 - 522
  • [8] SAFETY AND EFFICACY OF VANIPREVIR (MK-7009) IN COMBINATION WITH PEG-INTERFERON ALFA-2A (PEG-IFN)/RIBAVIRIN (RBV) IN GENOTYPE 1 TREATMENT EXPERIENCED HCV-INFECTED JAPANESE PATIENTS
    Hayashi, Norio
    Nakamura, Keisuke
    Wright, Duncan Hamish
    Caro, Luzelena
    Barnard, Richard J.
    Mobashery, Niloufar
    Tanaka, Yoshiyuki
    HEPATOLOGY, 2011, 54 : 996A - 996A
  • [9] MIXED TREATMENT COMPARISONS TO COMPARE SIMEPREVIR WITH BOCEPREVIR AND TELAPREVIR IN COMBINATION WITH PEG-INTERFERON ALPHA AND RIBAVIRIN (PR) IN PATIENTS INFECTED WITH GENOTYPE 1 HEPATITIS C VIRUS (HCV)
    Taieb, V
    Pacou, M.
    Van Sanden, S.
    Sbarigia, U.
    Mehnert, A.
    Duchesne, I
    VALUE IN HEALTH, 2014, 17 (07) : A665 - A665
  • [10] PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) FOLLOWING FIXED DOSING IN TREATMENT-NAiVE HEPATITIS C SUBJECTS (SINGLE DOSE INTERIM DATA FROM A DOSE-RANGING PHASE 2A STUDY)
    Byrnes-Blake, Kelly A.
    Freeman, Jeremy A.
    Rapalus, Lisa
    Pederson, Susan
    Fontana, David
    Lopez-Talavera, Juan Carlos
    Kansra, Vikram
    Miller, Dennis M.
    HEPATOLOGY, 2010, 52 (04) : 720A - 721A
12345